Halozyme Therapeutics (HALO) Kev ntsuas ntawv
Halozyme Therapeutics
Nqi dhau los$113.91Hloov kho 25 Sep 2026 19:59 UTC
Hloov-1.14%
AI kev txhais lus: HALO
AI tshaj tawm tus nqi hom phiaj rau hnub lag luam tom ntej, kawg lub lis thiab kawg hli. Kev hloov kho raug ntsuas los ntawm tus nqi tshiab. Cov no yog kev ntsuas xav tau, tsis yog kev pab cuam lag luam.
Nqi hauv 6 hli dhau los
Premium qhia AI lub hom phiaj nqi rau 1 hnub, 1 lim tiam thiab 1 hli rau tus no thiab txhua tus stock lwm tus.
Qhib Premium🔒 Kev ntsuas kev txav chav
Kev ntsuas kev txav chav — txhua kev ntsuas dhau los nyob ze rau qhov kawg tiag tiag — yog ib feem ntawm Premium.
Qhib PremiumTxog lub tuam txhab no
Halozyme Therapeutics, Inc. is a biopharmaceutical company that produces treatments for diabetes, cancer, and skin diseases. The company focuses on developing new drug delivery methods. Its technology platform is based on recombinant human hyaluronidase and additional enzymes.
